Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHX-2011
- Development stage
- Phase 3
- Lead developer
- CSPC Ouyi Pharmaceutical
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SYHX-2011 is an investigational small molecule antineoplastic drug developed by CSPC Ouyi Pharmaceutical for the treatment of advanced and metastatic breast cancer. It is a novel nano-preparation based on paclitaxel (albumin-bound type), designed to improve efficacy, safety, and compatibility compared to existing therapies. The drug is administered intravenously and has independent intellectual property rights. Its primary indication is for patients with metastatic breast cancer who have failed combination chemotherapy or experienced recurrence within six months after adjuvant chemotherapy. The precise mechanism of action remains undefined, but it builds upon the established cytotoxic effects of taxanes in breast cancer therapy[1][2][5][7].
- Other names
- syhx2011syhx-2011syhx 2011
Beyond the preview
Go deeper on SYHX-2011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHX-2011.